Your browser doesn't support javascript.
loading
Spontaneous regression of a metastatic carcinoma transmitted by a kidney graft.
Kiselevskiy, Mikhail V; Gromova, Elena G; Kozlov, Nikolay A; Bezhanova, Svetlana D; Shubina, Irina Zh.
Afiliação
  • Kiselevskiy MV; Laboratory of Cell Immunity, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow 115552, Russia.
  • Gromova EG; Intensive Care Unit, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow 115552, Russia.
  • Kozlov NA; Pathology Department, Division of Morphological and Molecular Genetic Diagnostics of Tumors, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow 115552, Russia.
  • Bezhanova SD; Pathology Department, Division of Morphological and Molecular Genetic Diagnostics of Tumors, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow 115552, Russia.
  • Shubina IZ; Laboratory of Cell Immunity, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow 115552, Russia.
Explor Target Antitumor Ther ; 4(3): 511-518, 2023.
Article em En | MEDLINE | ID: mdl-37455824
ABSTRACT
Transmission of a malignancy from a donor's organ to the recipient of the graft is a rare event, though it is a severe complication that can result in a poor outcome. Usually, immunosuppressive therapy is discontinued and the allograft is removed. However, treatment of patients with the disseminated cancers implies that after the graft removal and cessation of the immunosuppression, radiotherapy, chemotherapy, or immunotherapy with alpha-interferon (INF-α) or interleukin-2 (IL-2) are required. The case report presents a clinical case of a transmitted kidney graft with multiple metastases (MTS) in a 31-year-old woman with the spontaneous regression of the metastatic cancer after transplantectomy and cancellation of the immunosuppressive therapy. Obviously, the determining factor is the recognition of the tumor by the effectors of the antitumor immunity due to the human leukocyte antigen (HLA) mismatch between the donor and the recipient. Therefore, cancellation of the immunosuppressive therapy in cases of transferal of a malignancy with a transplanted organ allows the effectors of the immune system to distinguish the tumor as a foreign tissue and effectively eliminate this neoplasm.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Explor Target Antitumor Ther Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Explor Target Antitumor Ther Ano de publicação: 2023 Tipo de documento: Article